Mid-weight oncology stocks: The dark horses of cancer research
18 No. of Symbols
−0.70USD
−87.97 MUSD
591.64 MUSD
126.18 M
About NeoGenomics, Inc.
Sector
Industry
CEO
Christopher Michael Smith
Website
Headquarters
Fort Myers
Employees (FY)
2.1 K
Founded
1998
ISIN
US64049M2098
FIGI
BBG000BKH263
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Curated watchlists where NEO is featured.
Frequently Asked Questions
The current price of NEO is 13.77 USD — it has increased by 0.66% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange NeoGenomics, Inc. stocks are traded under the ticker NEO.
NeoGenomics, Inc. is going to release the next earnings report on Apr 30, 2024. Keep track of upcoming events with our Earnings Calendar.
NEO stock is 3.45% volatile and has beta coefficient of 1.81. Check out the list of the most volatile stocks — is NeoGenomics, Inc. there?
One year price forecast for NeoGenomics, Inc. has a max estimate of 30.00 USD and a min estimate of 18.00 USD.
NeoGenomics, Inc. revenue for the last quarter amounts to 151.95 M USD despite the estimated figure of 141.67 M USD. In the next quarter revenue is expected to reach 152.54 M USD.
Yes, you can track NeoGenomics, Inc. financials in yearly and quarterly reports right on TradingView.
NEO stock has fallen by 4.77% compared to the previous week, the month change is a 5.03% fall, over the last year NeoGenomics, Inc. has showed a 9.59% decrease.
NEO net income for the last quarter is −14.33 M USD, while the quarter before that showed −18.52 M USD of net income which accounts for 22.63% change. Track more NeoGenomics, Inc. financial stats to get the full picture.
Today NeoGenomics, Inc. has the market capitalization of 1.76 B, it has increased by 0.27% over the last week.
No, NEO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NEO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NeoGenomics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 2.10 K employees. See our rating of the largest employees — is NeoGenomics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NeoGenomics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NeoGenomics, Inc. stock shows the sell signal. See more of NeoGenomics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on NeoGenomics, Inc. future price: according to them, NEO price has a max estimate of 30.00 USD and a min estimate of 18.00 USD. Read a more detailed NeoGenomics, Inc. forecast: see what analysts think of NeoGenomics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NeoGenomics, Inc. EBITDA is −19.42 M USD, and current EBITDA margin is −4.07%. See more stats in NeoGenomics, Inc. financial statements.